Serum immunogloblins might be useful predictors of immune‐related adverse events after immune checkpoint inhibitor usage in lung cancer

We herein report a 79‐year‐old woman who underwent surgery had recurred non‐small cell lung cancer and developed irAEs following ICI treatment. During ICI treatment, we conducted monthly measurements of the serum antibody levels in this patient, including those which were both tumor‐ (anti‐p53 antib...

Descripción completa

Detalles Bibliográficos
Autores principales: Yasuda, Manabu, Take, Nobuyuki, Shinohara, Shinji, Chikaishi, Yasuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436670/
https://www.ncbi.nlm.nih.gov/pubmed/35869681
http://dx.doi.org/10.1111/1759-7714.14573
_version_ 1784781421650378752
author Yasuda, Manabu
Take, Nobuyuki
Shinohara, Shinji
Chikaishi, Yasuhiro
author_facet Yasuda, Manabu
Take, Nobuyuki
Shinohara, Shinji
Chikaishi, Yasuhiro
author_sort Yasuda, Manabu
collection PubMed
description We herein report a 79‐year‐old woman who underwent surgery had recurred non‐small cell lung cancer and developed irAEs following ICI treatment. During ICI treatment, we conducted monthly measurements of the serum antibody levels in this patient, including those which were both tumor‐ (anti‐p53 antibody) and nonspecific (immunoglobulins). Anti‐p53 antibodies and IgM had not increased during ICI treatment, but the serum levels of IgG and IgA had gradually increased before the occurrence of irAEs. These results suggest that monitoring serum immunoglobulin levels might enable the early detection of ICI‐induced immune responses in patients with lung cancer.
format Online
Article
Text
id pubmed-9436670
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-94366702022-09-09 Serum immunogloblins might be useful predictors of immune‐related adverse events after immune checkpoint inhibitor usage in lung cancer Yasuda, Manabu Take, Nobuyuki Shinohara, Shinji Chikaishi, Yasuhiro Thorac Cancer Case Reports We herein report a 79‐year‐old woman who underwent surgery had recurred non‐small cell lung cancer and developed irAEs following ICI treatment. During ICI treatment, we conducted monthly measurements of the serum antibody levels in this patient, including those which were both tumor‐ (anti‐p53 antibody) and nonspecific (immunoglobulins). Anti‐p53 antibodies and IgM had not increased during ICI treatment, but the serum levels of IgG and IgA had gradually increased before the occurrence of irAEs. These results suggest that monitoring serum immunoglobulin levels might enable the early detection of ICI‐induced immune responses in patients with lung cancer. John Wiley & Sons Australia, Ltd 2022-07-22 2022-09 /pmc/articles/PMC9436670/ /pubmed/35869681 http://dx.doi.org/10.1111/1759-7714.14573 Text en © 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Reports
Yasuda, Manabu
Take, Nobuyuki
Shinohara, Shinji
Chikaishi, Yasuhiro
Serum immunogloblins might be useful predictors of immune‐related adverse events after immune checkpoint inhibitor usage in lung cancer
title Serum immunogloblins might be useful predictors of immune‐related adverse events after immune checkpoint inhibitor usage in lung cancer
title_full Serum immunogloblins might be useful predictors of immune‐related adverse events after immune checkpoint inhibitor usage in lung cancer
title_fullStr Serum immunogloblins might be useful predictors of immune‐related adverse events after immune checkpoint inhibitor usage in lung cancer
title_full_unstemmed Serum immunogloblins might be useful predictors of immune‐related adverse events after immune checkpoint inhibitor usage in lung cancer
title_short Serum immunogloblins might be useful predictors of immune‐related adverse events after immune checkpoint inhibitor usage in lung cancer
title_sort serum immunogloblins might be useful predictors of immune‐related adverse events after immune checkpoint inhibitor usage in lung cancer
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436670/
https://www.ncbi.nlm.nih.gov/pubmed/35869681
http://dx.doi.org/10.1111/1759-7714.14573
work_keys_str_mv AT yasudamanabu serumimmunogloblinsmightbeusefulpredictorsofimmunerelatedadverseeventsafterimmunecheckpointinhibitorusageinlungcancer
AT takenobuyuki serumimmunogloblinsmightbeusefulpredictorsofimmunerelatedadverseeventsafterimmunecheckpointinhibitorusageinlungcancer
AT shinoharashinji serumimmunogloblinsmightbeusefulpredictorsofimmunerelatedadverseeventsafterimmunecheckpointinhibitorusageinlungcancer
AT chikaishiyasuhiro serumimmunogloblinsmightbeusefulpredictorsofimmunerelatedadverseeventsafterimmunecheckpointinhibitorusageinlungcancer

Ejemplares similares